BioCentury | Aug 4, 2017
Clinical News

FDA approves Jazz's Vyxeos for AML

...in a 1:5 molar ratio using CombiPlex technology. Jazz gained Vyxeos through its acquisition of Celator Pharmaceuticals Inc....
BioCentury | Jul 29, 2017
Finance

Show us your shorts

...I. 10/15/15 - USPTO PTAB denies Xyrem review J. 5/31/16 - Announces plans to acquire Celator Pharmaceuticals Inc....
BioCentury | Jun 2, 2017
Clinical News

FDA grants Priority Review to NDA for Jazz’s Vyxeos

...and daunorubicin encapsulated at a 5:1 molar ratio using CombiPlex technology, through its acquisition of Celator Pharmaceuticals Inc....
BioCentury | Jun 1, 2017
Company News

Jazz's Vyxeos under Priority Review for AML

...molar ratio using CombiPlex technology. Jazz gained the candidate through its $1.5 billion acquisition of Celator Pharmaceuticals Inc....
BioCentury | Apr 14, 2017
Clinical News

Vyxeos regulatory update

...breakthrough therapy designation in the U.S. for AML. Jazz gained Vyxeos through its acquisition of Celator Pharmaceuticals Inc....
BioCentury | Dec 10, 2016
Product Development

AML advances

...in patients unfit for chemotherapy. Vyxeos has breakthrough therapy designation for the indication. In March, Celator Pharmaceuticals Inc....
BioCentury | Oct 10, 2016
Clinical News

Vyxeos regulatory update

...therapy designation in the U.S. for AML. Jazz gained Vyxeos through its July acquisition of Celator Pharmaceuticals Inc....
BioCentury | Oct 3, 2016
Company News

Jazz begins Vyxeos NDA submission

...acquisition of Celator Pharmaceuticals Inc. , which closed in July (see BioCentury, June 6) . In March, Celator...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...with clinical or regulatory milestones expected in 3Q16. (A) Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is acquiring Celator Pharmaceuticals Inc.(NASDAQ:CPXX...
...Cerliponase alfa Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease Submit BLA and MAA Mid-2016 Celator Pharmaceuticals Inc....
BioCentury | Jul 11, 2016
Finance

Shedding red

...quarter. Through the first half, the band has fallen 25.1% and is the worst-performing segment. Celator Pharmaceuticals Inc....
...announced plans to buy Celator for $1.5 billion in cash, or about a 73% premium. Celator...
...announced plans to wind down operations. Companies and Institutions Mentioned Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Celator Pharmaceuticals Inc....
Items per page:
1 - 10 of 103
BioCentury | Aug 4, 2017
Clinical News

FDA approves Jazz's Vyxeos for AML

...in a 1:5 molar ratio using CombiPlex technology. Jazz gained Vyxeos through its acquisition of Celator Pharmaceuticals Inc....
BioCentury | Jul 29, 2017
Finance

Show us your shorts

...I. 10/15/15 - USPTO PTAB denies Xyrem review J. 5/31/16 - Announces plans to acquire Celator Pharmaceuticals Inc....
BioCentury | Jun 2, 2017
Clinical News

FDA grants Priority Review to NDA for Jazz’s Vyxeos

...and daunorubicin encapsulated at a 5:1 molar ratio using CombiPlex technology, through its acquisition of Celator Pharmaceuticals Inc....
BioCentury | Jun 1, 2017
Company News

Jazz's Vyxeos under Priority Review for AML

...molar ratio using CombiPlex technology. Jazz gained the candidate through its $1.5 billion acquisition of Celator Pharmaceuticals Inc....
BioCentury | Apr 14, 2017
Clinical News

Vyxeos regulatory update

...breakthrough therapy designation in the U.S. for AML. Jazz gained Vyxeos through its acquisition of Celator Pharmaceuticals Inc....
BioCentury | Dec 10, 2016
Product Development

AML advances

...in patients unfit for chemotherapy. Vyxeos has breakthrough therapy designation for the indication. In March, Celator Pharmaceuticals Inc....
BioCentury | Oct 10, 2016
Clinical News

Vyxeos regulatory update

...therapy designation in the U.S. for AML. Jazz gained Vyxeos through its July acquisition of Celator Pharmaceuticals Inc....
BioCentury | Oct 3, 2016
Company News

Jazz begins Vyxeos NDA submission

...acquisition of Celator Pharmaceuticals Inc. , which closed in July (see BioCentury, June 6) . In March, Celator...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...with clinical or regulatory milestones expected in 3Q16. (A) Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is acquiring Celator Pharmaceuticals Inc.(NASDAQ:CPXX...
...Cerliponase alfa Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease Submit BLA and MAA Mid-2016 Celator Pharmaceuticals Inc....
BioCentury | Jul 11, 2016
Finance

Shedding red

...quarter. Through the first half, the band has fallen 25.1% and is the worst-performing segment. Celator Pharmaceuticals Inc....
...announced plans to buy Celator for $1.5 billion in cash, or about a 73% premium. Celator...
...announced plans to wind down operations. Companies and Institutions Mentioned Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Celator Pharmaceuticals Inc....
Items per page:
1 - 10 of 103